Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7687 · 3 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Active | EXPERIMENTAL | AZD7687 oral suspension |
| Placebo | EXPERIMENTAL | placebo oral suspension |
| Name | Type | Description |
|---|---|---|
| AZD7687 | DRUG | Oral suspension |
| Placebo | DRUG | Oral suspension, once daily. Totally 8 doses |
Inclusion Criteria: * Suitable veins for cannulation or repeated venipuncture * Have a body mass index (BMI) between 19 and 35 kg/m2 and weigh at least 50 kg and no more than 90 kg * Male subjects should be willing to use barrier contraception ie, condoms with spermicide, from the first day of dosi...
AZD7687 is an investigational small molecule being studied for use in healthy volunteers, overweight and obese individuals, and patients with Type 2 Diabetes. It has been evaluated in early-stage clinical trials to assess its safety, tolerability, and blood levels, but it is not approved for any indication.
AZD7687 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company has sponsored Phase 1 clinical trials to investigate the drug's properties in various populations.
AZD7687 is in Phase 1 clinical development. All completed trials for this drug are Phase 1 studies, meaning it is still in early-stage testing to evaluate safety, tolerability, and pharmacokinetics in humans. It remains investigational and has not received regulatory approval.
AZD7687 has been studied in three completed Phase 1 trials: NCT01046357, a single ascending dose study in healthy volunteers in the United States; NCT01119352, a multiple ascending dose study in overweight and obese participants in the United Kingdom; and NCT01217905, a Japanese single and multiple ascending dose study in patients with Type 2 Diabetes and obesity.
No, AZD7687 is not FDA approved. It is an investigational drug that has only been tested in Phase 1 clinical trials, which are designed to assess basic safety and tolerability. The drug has not progressed to later-stage trials or received marketing authorization from regulatory agencies.